Biological processes that govern our lives are many, intertwined, and often difficult to understand. They involve countless ...

In this whitepaper, Gattefossé Pharmaceuticals seeks to bridge the gap between lipid-based formulations and oral solid dosage ...

In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...

CKD patients face higher CVD risk, with dyslipidemia differing from the general population, necessitating tailored lipid ...

Schematic illustration showing the classification of lipid‐based nanocarriers (LBNCs) (including liposomes, micelles, nanoemulsions, SLNs/NLCs, LNPs, BLNs, SRLNCs) and their targeted delivery to ...

As lipid-based nanoparticles continue to revolutionize therapeutic delivery, this guide will provide cutting-edge insights, emerging applications, and expert strategies to help you stay at the ...

Table 2. Stable nucleic acid lipid particle formulations. Stable nucleic acid lipid particle formulations in systemic delivery Target siRNA and modification (yes/no) Animal model Ref.

LNPs are solid or semi-solid particles at room temperature. They are composed of a lipid core stabilized by surfactants or other agents. This lipid core provides a hydrophobic environment ideal for ...

Nanomedicine shows great promise in drug delivery due to its versatility in drug loading and ability to target the tissue of interest; however, its current applicability is significantly hindered by ...

The global lipid nanoparticle manufacturing market size was valued at USD 475 million in 2025 and is predicted to hit around ...